Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495317 | 0.87 | NPC1 (0.41) | ATRKDM4EALDH1A1NPSR1MAPT | |
| SCHEMBL21930986 | 0.87 | ALDH1A1 (0.47) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL1681287 | 0.86 | IKBKB (0.39) | HSD17B10KDM4EALDH1A1MAPTMAPK1 | |
| SCHEMBL22774379 | 0.82 | CA1 (0.44) | LCKSMN1; SMN2MEN1KMT2ACA1 | |
| SCHEMBL13348132 | 0.81 | HSD17B10 (0.54) | HSD17B10ATRKDM4EALDH1A1HPGD | |
| SCHEMBL26164994 | 0.79 | LCK (0.37) | LCKRXFP1 | |
| SCHEMBL1563630 | 0.79 | CHEK1 (0.45) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL5425234 | 0.78 | KDM4E (0.36) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL5728164 | 0.78 | CUL4A (0.38) | KDM4EALDH1A1LCKCA1CA2 | |
| SCHEMBL3496455 | 0.78 | ALDH1A1 (0.58) | HSD17B10KDM4EALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023101556-A1 | NOVEL INHIBITORS OF ASPARTATE TRANSCARBAMOYLASE (ATCASE) AND COMPOSITIONS, METHODS AND USES RELATED THERETO. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101556-A1 | NOVEL INHIBITORS OF ASPARTATE TRANSCARBAMOYLASE (ATCASE) AND COMPOSITIONS, METHODS AND USES RELATED THERETO. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-06-08 | — | — | WO | disclosed |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070099929-A1 | Substituted thiophenes | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099929-A1 | Substituted thiophenes | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099929-A1 | Substituted thiophenes | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TNNC1, CPT1B, TNNI3 | HSD17B10 232/4885ATR 410/4885KDM4E 1496/4885 |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | HSD17B10 92/4885ATR 207/4885KDM4E 1730/4885 |
| US-20070099929-A1 | Substituted thiophenes | TPMT, HAVCR2, MTAP | HSD17B10 2854/4885ATR 3031/4885KDM4E 2012/4885 |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | PDE4A, PDE4B, PDE7A | HSD17B10 1307/4885ATR 2735/4885KDM4E 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.